Fadi Haddad/X
Dec 12, 2024, 14:22
Fadi Haddad: Happy to present data on the role of inotuzumab in patients with B-ALL at ASH24
Fadi Haddad, Assistant Professor in the Department of Leukemia at the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, shared a post on X:
“Happy to present data from MD Anderson Cancer Center on the role of inotuzumab in eradicating MRD in patients with B-ALL at ASH24:-
- N=30
- 67% response rate, MRD conversion
- 3-year OS 56%
- Low grade AEs, but 2 SOS (both in patients with ponatinib, Gr 5=1).”
Fadi Haddad is an Assistant Professor in the Department of Leukemia at the Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center in Houston, TX. He serves as a member of the Leading Clinical Research Faculty Learning Series. His postgraduate training includes a clinical fellowship in leukemia at MD Anderson Cancer Center and a clinical residency in hematology/oncology at Hotel Dieu de France Hospital in Beirut.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 15, 2025, 13:00
Jan 15, 2025, 11:08
Jan 15, 2025, 08:14
Jan 15, 2025, 07:53